HEALWELL has completed the equity tranche of its previously announced upsized $55 million bought deal financing, raising gross proceeds of $25.5M. The proceeds of the financing will be used to… Read More
Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care… Read More
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms… Read More
TORONTO, ON – LifeLabs is proud to announce that it has been named Canada’s Most Trusted Health Diagnostic Service Provider for the third year in a row by the 2025… Read More
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer’s Statistically significant reduction in neurodegeneration marker, neurofilament light chain (‘NfL’) mRNA profile showed a reduction of several key neuroinflammatory genes in the… Read More
